I was going to comment that there is no apparent AH activity, then several trades showed up.
Last one at 4:36pm , 1,350 shares @ $2.12, which brings us up to a grand total of a 20.78% gain for the day.
Some news leaking out somewhere?
I guess SQNM is not to "First to Market".
Liquid biopsy cancer screening goes mainstream (Seeking Alpha Article)
Privately-held Pathway Genomics announces the availability of cancer screening from blood samples for as little as $299 per test. The test, called a liquid biopsy, measures small DNA fragments circulating in the blood that have been shed by cancer cells. The value proposition is lower cost and less invasive compared to a tissue biopsy which requires a needle aspirate. A tissue biopsy can be painful for the patient, especially if a second procedure is required, not uncommon considering that ~20% fail to obtain sufficient tumor tissue to analyze.The company's offering, CancerIntecept, analyzes 96 frequently occurring DNA mutations in nine genes associated with lung, breast, ovarian and colorectal, pancreatic, head and neck, thyroid, gastric and prostate cancers in addition to melanoma. CancerIntercept Detect is targeted for high-risk but otherwise healthy patients while CancerIntercept Monitor is for patients with active or previously diagnosed cancer.The test is performed by Pathway in its CLIA-certified laboratory. Patients can access the test through their own physician or via the company's referral network. Repeat testing on a scheduled basis is available on a deeply discounted basis (since there is no reimbursement). A mobile phlebotomist will even come to the patient's home to draw the blood sample.Related tickers: (TBIO +3.4%)(BIOC +2.8%)(TROV -1.3%)